Constitutively produced nitric oxide released by endothelial cells has been shown to act as an endogenous agent which inhibits the rolling and adhesion of leucocytes in the microcirculation. However, during various types of inflammation, expression of the inducible form of nitric oxide synthase (iNOS) can dramatically increase the amount of nitric oxide present in tissues. Furthermore, as iNOS can be expressed by a wide variety of cell types, the distribution of nitric oxide is likely to be altered relative to that in unstimulated tissue. Under these conditions, it is less well understood whether iNOS-derived nitric oxide retains the anti-adhesive capabilities of constitutively produced nitric oxide. This review summarizes work done to examine this issue. Three main approaches have been used. In vitro studies have examined the role of iNOS in adhesive interactions between stimulated endothelial cells and leucocytes, providing evidence of an anti-adhesive effect of iNOS. In addition, the role of iNOS has been examined in vivo in animal models of inflammation using pharmacological iNOS inhibitors. These experiments were extended by the advent of the iNOS-deficient (iNOS − / − ) mouse. Intravital microscopy studies of these mice have indicated that, under conditions of low-dose endotoxaemia, iNOS-derived nitric oxide can inhibit leucocyte rolling and adhesion. The potential mechanisms for these effects are discussed. In contrast, several other studies have observed either no effect or an enhancing effect of iNOS on inflammatory leucocyte recruitment. Taken together, these studies suggest that the importance of iNOS in modulating leucocyte recruitment can vary according to the type of inflammatory response.
INTRODUCTION
The inflammatory response, normally induced by infection or tissue injury, is crucial in controlling and ultimately eliminating infectious agents, as well as in promoting wound healing for restoration of tissue integrity. However, if the immune system is inappropriately stimulated or normal regulation is lost, the inflammatory response can cause injury to host tissues. These so-called ' inappropriate ' inflammatory responses contribute to the pathogenesis of a wide range of recruitment. It is becoming clear that nitric oxide (NO) is one such compound. NO is produced continuously by endothelial cells lining the vasculature via a constitutively expressed isoform of the NO synthase (NOS) enzyme, i.e. endothelial NOS (eNOS). Inhibition of this enzyme induces leucocyte recruitment to tissues, even in the absence of additional inflammatory stimulation. In addition, NO has been shown to inhibit platelet aggregation and to promote tissue perfusion via regulation of vascular tone. All of these functions have been attributed to NO produced by the constitutive eNOS isoform.
However, under a wide range of inflammatory conditions, another isoform of NOS, known as inducible NOS (iNOS), can be expressed. iNOS differs from eNOS in its cellular distribution, regulation and output. As iNOS is expressed almost exclusively under inflammatory conditions, this has led to the hypothesis that iNOS has detrimental effects in inflamed tissues, and promotes the inflammatory process. However, as iNOS is expressed when leucocyte recruitment is occurring at a rapid rate, i.e. during the inflammatory response, the issue of whether iNOS-derived NO is capable of regulating leucocyte recruitment is highly pertinent. Only recently have investigators begun to examine this issue. In this review I will provide some background on the process of leucocyte recruitment and the data implicating constitutively produced NO as an anti-adhesive molecule in the microcirculation. Then I will examine iNOS and review the data relating to iNOS and leucocyte adhesion, including a discussion of the potential mechanisms for the effects observed, and issues warranting further investigation.
LEUCOCYTE RECRUITMENT
Leucocyte recruitment to sites of inflammation entails a sequence of interactions between leucocytes moving rapidly in the bloodstream and endothelial cells lining the microvasculature (for reviews, see [1,2]) (Figure 1 ) Contact between the two cell types is initiated when leucocytes tether on to the endothelium, and then start rolling along the endothelial surface. Rolling leucocytes are then able to undergo an activation event that induces them to stop rolling and adhere firmly to the endothelium. Once adherent, leucocytes are able to emigrate out of the vasculature and enter the inflammatory site. This sequence of events is orchestrated by activated microvascular endothelial cells in the inflamed tissue, via expression of a number of molecules with specific functions in capturing and activating leucocytes. Specific groups of proteins, i.e. adhesion molecules and chemoattractants\chemokines, mediate each step in this sequence.
The initial step of tethering and rolling is mediated by the selectin family of adhesion molecules and, in some cases, by the leucocyte α4-integrin. The role played by these molecules is critical, in that they initiate interactions between endothelial cells and rapidly moving leucocytes in the blood. The importance of this initial interaction is illustrated by the observation that blockade of selectinmediated rolling prevents subsequent adhesion and emigration [3, 4] . The selectins consist of P-selectin and E-selectin expressed by activated endothelial cells, and L-selectin, which is constitutively expressed by most circulating leucocytes. P-selectin is stored pre-formed in Weibel-Palade bodies of endothelial cells [5] , and is rapidly mobilized (within 5-15 min) from this source to the endothelial surface in response to stimulation with mediators such as thrombin, histamine and C5a, a product of complement activation [6, 7] . Oxidants such as H # O # also induce expression of P-selectin from preformed stores, but over a slower and more prolonged time course [8] . Longer-term, protein synthesisdependent expression of P-selectin can also be induced in response to stimulation with mediators such as tumour necrosis factor-α (TNF-α) and bacterial lipopolysaccharide (LPS ; endotoxin). E-selectin is not expressed under basal conditions, but its expression is also induced by inflammatory mediators such as TNF-α and LPS [9] .
The endothelial selectins bind to carbohydrate moieties expressed by leucocytes. P-selectin glycoprotein ligand-1 (PSGL-1) is the dominant leucocyte ligand for P-selectin [10] . An E-selectin-specific ligand (ESL-1) has been identified using affinity isolation with an E-selectin-Ig fusion protein ; however, the physiological role of this molecule is yet to be confirmed [11] . In addition, Eselectin can bind a carbohydrate epitope termed cutaneous lymphocyte antigen (CLA), which is expressed almost exclusively by skin-homing T-cells as a specialized form of PSGL-1 [12, 13] . Carbohydrate-bearing ligands for L-selectin have also been identified, expressed by activated endothelial cells such as those lining high endothelial venules in lymphoid tissue [14, 15] , and in chronically inflamed peripheral vascular beds [16] . The α4-integrin, expressed by eosinophils and mononuclear cells, has also been shown to mediate rolling of these leucocytes, both in vitro under flow conditions [17] and in vivo in specific models of inflammation [16, 18] . All of the molecules capable of mediating rolling have specialized capabilities which allow for capture of rapidly moving leucocytes from the mainstream of blood flow. The interactions between selectins and their ligands are characterized by rapid rates of bond formation and dissociation combined with high bond strength. These properties enable rolling leucocytes to roll along the vascular wall, rapidly forming new selectin bonds at the same time as dissociating from previous bonds.
For rolling leucocytes to progress to firm adhesion, they must undergo an activation step. The process of activation occurs when the leucocyte encounters a chemoattractant molecule presented on the endothelial Inducible NO synthase and leucocyte recruitment Leucocyte recruitment to inflammatory sites involves a cascade of interactions between leucocytes and endothelial cells. Initially, leucocytes moving rapidly in the blood come into contact (tether) with the endothelial surface and commence rolling along the endothelium. Rolling leucocytes are able to detect chemoattractant molecules on the endothelial surface, inducing activation and subsequent firm adhesion on the endothelial surface. Once adherent, leucocytes are able to emigrate into the extravascular tissue. Each step in this cascade of events is mediated by specific groups of molecules. Leucocyte rolling is mediated predominantly by the selectins and the α4-integrins. Activation is mediated by chemoattractant molecules, such as chemokines and PAF. Adhesion is mediated by interaction of leucocyte β2-and α4-integrins with members of the immunoglobulin superfamily (ICAM-1/VCAM-1). Abbreviations : MCP-1, monocyte chemotactic protein-1 ; PECAM-1, platelet-endothelial cell adhesion molecule-1.
surface, which interacts with a specific G-proteincoupled receptor expressed by the leucocyte. Molecules capable of mediating activation of rolling leucocytes include platelet-activating factor (PAF), interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) [6, [19] [20] [21] . These chemoattractant molecules also aid in guiding leucocytes into and throughout inflammatory sites [22] .
Firm adhesion of leucocytes is dependent on the interaction of leucocyte β2-and α4-integrins with their respective endothelial ligands, including intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) [2] . Polymorphonuclear neutrophils predominantly use the β2-integrins LFA-1 (lymphocyte function associated antigen-1) and Mac-1 to undergo adhesion during acute inflammatory responses [23] . In contrast, CD4 + T cells predominantly use the α4β1-integrin (very late activation antigen-4 ; VLA-4) for adhesion and β # -integrins for spreading and transmigration across the endothelium [24] . Monocytes are capable of using different combinations of β " -and β # -integrins for adhesion and transmigration, depending on the mediator used to stimulate the endothelium [25, 26] . In addition, molecules such as CD31 (platelet-endothelial cell adhesion molecule-1 ; PECAM-1) and the αvβ3-integrin have also been proposed to play a role in leucocyte transendothelial migration [27, 28] .
Finally, there is growing evidence that platelets, adherent to exposed subendothelial matrix or activated microvascular endothelium, can promote recruitment of leucocytes to an inflamed or injured microvascular bed.
In in vivo models of inflammation, such as balloon angioplasty and intestinal ischaemia\reperfusion, platelets co-localize with leucocytes at the inflamed site [29, 30] . Moreover, leucocytes can roll and adhere on monolayers of activated platelets under flow conditions in vitro, with platelet P-selectin and Mac-1 expressed by leucocytes playing important roles in these interactions [31] [32] [33] . These observations suggest that platelets may provide an additional pathway for leucocyte recruitment, further to that supplied by activated endothelial cells.
In summary, these basic paradigms apply both in homoeostatic leucocyte trafficking (e.g. lymphocyte recirculation) and in leucocyte-endothelial-cell interactions occurring during inflammatory responses. However, there is convincing evidence that individual tissues vary in the way they apply this paradigm, even in response to the same inflammatory stimulus [34] [35] [36] .
NITRIC OXIDE
Nitric oxide is a low-molecular-mass soluble mediator which is now implicated in a vast number of physiological processes. Most prominent among these are the control of vascular tone and platelet aggregation, neural transmission and cytostatic\cytotoxic effects against tumour cells and microbes (for reviews, see [37, 38] ). NO is produced by NOS using L-arginine and molecular oxygen as substrates, and yielding NO and L-citrulline as products [39] . NO can diffuse readily across cell membranes in order to interact with intracellular target molecules, including soluble guanylate cyclase. There are three known NOS isoforms. The two constitutively expressed isoforms are neuronal NOS (nNOS or NOS1), located predominantly in neurons, and eNOS\consti-tutive NOS (NOS3), expressed predominantly in endothelial cells. These enzymes are termed calciumdependent, as their activity is regulated by intracellular calcium levels. The third isoform, inducible NOS (iNOS or NOS2), is not constitutively expressed, but its expression can be induced in tissues undergoing inflammatory responses.
Constitutively produced NO and leucocyte recruitment
Ongoing production of small quantities of NO by eNOS in endothelial cells is critical in the regulation of vascular tone and tissue perfusion [40, 41] . Inhibition of this enzyme is possible using analogues of the NOS substrate L-arginine, such as N G -nitro-L-arginine methyl ester (L-NAME). Kubes et al. [42] used this approach to examine the role of continuously produced NO in the regulation of leucocyte-endothelial cell interactions. They showed that inhibition of NO production induced a profound increase in the number of adherent leucocytes in the microvasculature of the feline mesentery. Additional studies in the rat mesentery showed that L-NAME also increased leucocyte rolling [43] . These observations indicated that NO, continuously produced by endothelial cells, has an ongoing anti-inflammatory effect, in that it inhibits the rolling and adhesion of leucocytes to the endothelium. Similar observations have now been made in a wide range of tissues, including the liver, lung, heart and skeletal muscle, suggesting that this is a universal phenomenon throughout the microvasculature [44] [45] [46] [47] [48] [49] . Furthermore, it has also been shown that constitutively produced NO acts to attenuate leucocyte recruitment during inflammatory processes. Inhibition of NO production during exposure to LPS or H # O # exacerbates leucocyte recruitment, showing that endogenous production of NO continues to act as a control mechanism for leucocyte recruitment during certain types of inflammatory responses [47, 50] . Finally, NO also may also impact on the inflammatory response via its ability to inhibit adhesion of platelets to the endothelial surface [51] .
Mechanism of increased adhesion during inhibition of constitutive NO production
Investigators have examined the mechanism for this effect, with varying conclusions. Some data suggest that NO can directly inhibit endothelial expression of adhesion molecules such as P-selectin [43] . Other findings suggest that NO acts to inhibit oxidative stress in the microvasculature, through its established ability to neutralize the damaging oxidant superoxide [52] . Inhibition of NO synthesis has been shown to induce oxidative stress in skeletal muscle in vivo [48] and in human umbilical vein endothelial cells (HUVEC) in vitro [53] . Furthermore, the leucocyte recruitment that occurs subsequent to NOS inhibition can be blocked by scavenging oxidants such as superoxide [45, 48, 53, 54] , suggesting that the increase in oxidative stress in the microvasculature is responsible for the leucocyte recruitment induced following NOS inhibition. Oxidants such as the superoxide anion and hydrogen peroxide can act on endothelial cells directly to induce expression of adhesion molecules and pro-adhesive mediators such as PAF [8, 50, 55] . Furthermore, oxidative stress in vivo can induce activation of mast cells [45] . Mast cells are capable of releasing a wide range of mediators that promote leucocyte recruitment, including PAF, various chemokines, histamine and TNF-α [56, 57] . Mast cells in the rat mesentery have been shown to become activated during the inhibition of NO production by L-NAME [45] , suggesting that one of the protective effects of constitutively produced NO is to limit mast cell reactivity. Despite these observations, further studies are required to elucidate fully the mechanism behind the NOmediated inhibition of leucocyte adhesion. It is conceivable that the mechanism varies according to the cellular composition of the affected tissue and the type of the inflammatory response.
The anti-inflammatory capabilities of continuously produced NO have been studied extensively. However, under specific inflammatory conditions, an additional enzyme capable of NO synthesis, iNOS, can be expressed. Much less is known about the role of this inducible NOS enzyme in the regulation of inflammatory responses.
INDUCTION AND EXPRESSION OF iNOS
In non-inflamed healthy tissue, iNOS is normally not expressed. However, in response to stimulation with microbial byproducts and\or inflammatory cytokines, a wide range of cells can express iNOS. This capacity has been demonstrated in endothelial cells, hepatocytes, vascular smooth muscle cells, cardiac myocytes, skeletal muscle cells, chondrocytes and intestinal epithelial cells, as well as elements of the immune system, including macrophages and polymorphonuclear neutrophils (Figure 2) [58] . Although the specific stimuli that are effective in each cell type vary, iNOS induction is most commonly observed in response to inflammatory cytokines such as interferon-γ, TNF-α and IL-1, in addition to live microbes and microbial byproducts such as LPS [58] . Furthermore, in many cell types, iNOS is synergistically induced in response to stimulation with two or more of these agents in combination [58, 59] . Inducible NO synthase and leucocyte recruitment
Figure 2 Potential sites of iNOS expression in the vasculature
This figure illustrates the cell types potentially capable of expressing iNOS during inflammatory responses. iNOS expression has been detected in a wide range of cell types normally resident in the microvasculature. These include both intra-and extravascular leucocytes, endothelial cells and smooth muscle cells (SMC). In addition, parenchymal cells such as fibroblasts and epithelial cells (not shown) can be induced to express iNOS. The cellular distribution varies according to the type of inflammatory response.
The predominant biological functions of iNOS are thought to relate to macrophage-mediated host defence against tumour cells and micro-organisms [60, 61] . In vivo, expression of iNOS is normally correlated with infection and sepsis [39, 62] , or chronic inflammatory diseases such as inflammatory bowel disease and rheumatoid arthritis [63, 64] . However, there are examples of iNOS being ' constitutively ' expressed. iNOS has been detected in epithelial cells of the ileal mucosa in healthy mice and in the normal human pulmonary epithelium, in both cases in the absence of an obvious inflammatory response [65, 66] . It is conceivable that persistent iNOS activity is responsible for ongoing control of potentially infectious micro-organisms in both of these tissues, suggesting a homoeostatic function for iNOS.
iNOS also differs from eNOS in the amount of NO produced. Whereas NO production by eNOS is tightly regulated, iNOS functions independently of intracellular calcium levels and produces much greater amounts of NO by continually producing NO for the life of the enzyme [58] . This ability has raised the question of whether this enzyme produces damaging amounts of NO, potentially via generation of more potent oxidants such as peroxynitrite [67] . However, recent studies suggest that iNOS-derived NO retains many of the antiinflammatory effects of the constitutive isoform.
EXAMINATION OF THE EFFECTS OF iNOS IN VITRO
Several studies have examined the effects of iNOSderived NO using in vitro adhesion systems. Cartwright et al. [68] created murine macrophage cell lines that express either sense or antisense oligonucleotides to murine iNOS. Following stimulation with LPS, cells expressing iNOS antisense oligonucleotides produced significantly less iNOS protein and NO than lines expressing the sense oligonucleotides. Furthermore, cells expressing high levels of iNOS antisense oligonucleotides underwent adhesion to endothelial cells much more efficiently than sense-transfected cells [68] . These observations suggested that iNOS-derived NO is capable of regulating the adhesion of macrophage cell lines to endothelial cells. Peng et al. [69] used a similar approach by co-culturing the murine macrophage cell line RAW264.7 with cytokine-stimulated endothelial cells. When RAW264.7 cells were induced to express iNOS by murine interferon-γ and LPS, and added to stimulated endothelial cells, adhesion of the leucocyte cell line was significantly enhanced if NO production was inhibited with the L-arginine analogue N G -monomethyl-L-arginine. Interestingly, further experiments in that study suggested that the NO produced by the leucocytes was impacting on the endothelial cells in co-culture. Coculture of RAW264.7 cells and endothelial cells in the presence of LPS induced iNOS expression in the RAW264.7 cells and endothelial VCAM-1 expression. Inhibition of iNOS-derived NO production by RAW264.7 cells caused a 3n6-fold increase in VCAM-1 expression by endothelial cells. It is important to note that the combination of LPS and murine cytokines used in these experiments did not induce iNOS expression by the human endothelial cells, and therefore iNOS was restricted to the RAW264.7 cells. This intriguing observation provided the first indication that NO produced by leucocyte-derived iNOS is capable of influencing the expression of adhesion molecules by adjacent endothelial cells. However, this result occurred under conditions of an extended 24 h co-culture using a cell type (RAW264.7) which has the capacity to produce more iNOS and NO than most known mammalian cell types. Further studies are required to determine whether these findings extend to the inflamed microvasculature in vivo.
During inflammatory responses, iNOS expression can occur in many cell types other than leucocytes. Binion et al. [70] have examined the role of iNOS expressed by endothelial cells. Stimulation of human intestinal microvascular endothelial cells (HIMEC) for 24 h with TNF-α and LPS induced iNOS mRNA expression and a 2n5-fold increase in NO production, indicating that this treatment was sufficient to induce iNOS expression in HIMEC. TNF-α\LPS treatment also induced adhesion of the U-937 monocyte-like cell line to HIMEC. However, in the presence of the iNOS-specific inhibitor Niminoethyl-L-lysine (L-NIL), U-937 adhesion was significantly enhanced. To determine if the increased adhesion was due to alterations in endothelial adhesion molecule expression, the authors measured the expression of Eselectin, ICAM-1 and VCAM-1. Interestingly, despite the significant alterations in U-937 cell adhesion on L-NIL-treated endothelial cells, no alterations in the surface expression of any of the three adhesion molecules were detected. However, iNOS inhibition was associated with increased oxidative stress in the activated endothelial cells. Furthermore, the increased adhesion could be attenuated with the superoxide scavenger, polyethylene glycol-superoxide dismutase. These findings indicated that iNOS-derived NO may function in an antiinflammatory manner by lowering oxidant levels in activated endothelial cells, and that elevated oxidant levels during iNOS inhibition were responsible for increased adhesion [70] . While the mechanism linking oxidant stress and increased leucocyte adhesion is unknown, these findings clearly show that iNOS expression by microvascular endothelial cells can decrease leucocyte adhesion.
An additional important finding from the study of Binion et al. [70] was the difference in the responsiveness of HUVEC. The TNF-α\LPS treatment that induced iNOS in HIMEC failed to induce iNOS expression in HUVEC, and iNOS inhibition had no effect on leucocyte binding to HUVEC. Furthermore, adhesion molecule expression in microvascular endothelial cells was not affected by high levels of NO, in direct contrast with many experiments using macrovascular endothelial cells. These findings illustrate that endothelial cells derived from these distinct locations can display markedly differing phenotypes, indicating important functional differences between microvascular and macrovascular endothelial cells. Clearly, if the results of in vitro experiments are to be extrapolated to the microcirculation in vivo, it is important, wherever possible, to study cell types that display a similar phenotype to those resident in the microcirculation.
EFFECTS OF iNOS INHIBITION IN VIVO
Prior to the advent of gene targeting, examination of a role for iNOS in in vivo physiology was difficult. The initial breakthroughs in the NOS field were made using L-arginine analogues to inhibit NOS activity. Due to the structural similarities of the NOS isoforms, compounds which block the function of iNOS are also likely to impact on the activity of the constitutive NOS isoforms. Despite this, some compounds have been discovered that have greater effectiveness on one or other of the isoforms. Aminoguanidine, for example, has been shown to be selective for the iNOS isoform. Therefore we used this compound to examine the role of iNOS in the regulation of TNF-α-induced leucocyte rolling in the feline mesentery. Continuous superfusion of the mesentery with TNF-α induces a progressive increase in leucocyte rolling in mesenteric post-capillary venules, as well as inducing iNOS expression [71] . Treatment with the iNOS inhibitor aminoguanidine induced a further increase in the number of rolling leucocytes. The dose of aminoguanidine used had no effect on systemic blood pressure or baseline leucocyte rolling, indicating that it was not affecting eNOS. These findings suggested that iNOS was acting to regulate leucocyte rolling in this TNF-α-induced model of inflammation.
Comparable studies have examined the role of iNOS in a rat model of balloon catheter injury of the carotid artery [72] . This injury disrupts the endothelium, allowing platelets to accumulate on the exposed subendothelial surface, and causes induction of iNOS expression in the vascular wall adjacent to the area of injury. iNOS inhibition by either systemic or local administration of L-NAME significantly enhanced platelet accumulation on the vascular wall, and reduced blood flow in the injured carotid artery. These observations indicated that, following disruption of the endothelium and the associated loss of eNOS, induction of iNOS expression allowed iNOS-derived NO to assume the role of eNOS-derived NO, inhibiting platelet adhesion in the injured arterial segment and improving vessel patency.
In contrast, several other studies have shown no effect of iNOS inhibition on inflammatory leucocyte recruitment. In models of haemorrhagic shock-induced gastric mucosal injury and hepatic injury during endotoxaemia, iNOS inhibition using L-NIL and\or aminoguanidine did not modulate leucocyte recruitment into the injured organs [73, 74] . Similarly, in a rat model of oysterglycogen-induced peritonitis, L-NIL treatment had no effect on neutrophil extravasation into the peritoneal cavity [75] . These findings show that iNOS does not inhibit leucocyte recruitment in all models of inflammation. These disparate observations may be related to the varying inflammatory mechanisms involved in each model, or perhaps to tissue-specific differences such as the cellular localization of iNOS.
Although the above findings are undoubtedly of value, there remains some difficulty in assessing studies using pharmacological NOS inhibitors. Due to the structural similarities of the constitutive and inducible NOS isoforms, even the most iNOS-selective of the available pharmacological agents can have some effect on eNOS. Furthermore, some inhibitors have non-specific effects related to other enzyme systems, e.g. aminoguanidine interferes with metabolism of the pro-inflammatory mediator histamine [76] . Therefore a more direct method for examining the role of this enzyme in leucocyte recruitment was to use iNOS-deficient (iNOS −/− ) mice.
LEUCOCYTE TRAFFICKING AND INFLAMMATORY RESPONSES IN iNOS-DEFICIENT MICE

Modulation of leucocyte rolling and adhesion by iNOS
To examine the role of iNOS in leucocyte rolling and adhesion, we treated wild-type and iNOS −/− mice with LPS to allow for iNOS induction, and compared them using intravital microscopy [77] . At 2-4 h after LPS administration, leucocyte rolling and adhesion in postcapillary venules of the cremaster muscle were markedly enhanced in iNOS −/− mice relative to wild-type controls. Leucocyte recruitment in hepatic post-sinusoidal venules and in the pulmonary microvasculature were also enhanced in iNOS −/− mice. No differences were observed under constitutive conditions [77, 78] . These findings provided strong evidence that iNOS is an important homoeostatic regulator of leucocyte recruitment in the inflamed microcirculation.
iNOS in intestinal leucocyte recruitment
The role of iNOS in leucocyte recruitment has been examined in several other inflammatory models, including intestinal inflammation (for a review, see [79] ). In an acetic acid-induced model of acute colitis, iNOS −/− mice had difficulty in resolving the inflammation, and neutrophil infiltration persisted for several days longer than in wild-type mice [80] . In a more prolonged model of colitis induced by trinitrobenzene sulphonic acid, iNOS −/− mice also exhibited enhanced levels of neutrophil infiltration in the early stages of the inflammatory response ; however, this difference was no longer present 7 days after initiation of injury [81] . These findings provide further evidence that iNOS-derived NO can act as a homoeostatic regulator of inflammatory leucocyte recruitment.
Models of inflammation in which leucocyte recruitment is either unaffected or reduced in iNOS-deficient mice
In contrast with the studies in which iNOS had an inhibitory effect on leucocyte recruitment, several studies have observed either no alteration or a reduction in leucocyte recruitment in inflamed iNOS −/− mice. In one of the original descriptions of the iNOS −/− mouse, wild-type and iNOS −/− mice succumbed at the same rate to a model of septic shock induced by initial treatment with heat-killed Proprionibacterium acnes followed by injection of LPS [82] . Subsequent pathological examination of the liver and lungs revealed comparable levels of neutrophil margination in the vasculature following this treatment. Furthermore, leucocyte recruitment into the peritoneal cavity induced by interferon-γ and LPS, sodium periodate or thioglycollate was not altered in iNOS −/− mice. Clearly in these models, in which iNOS is expressed in wild-type mice, iNOSderived NO is without effect on total leucocyte accumulation. In other models, iNOS appears to enhance recruitment of leucocytes to the inflammatory site. For example, in a model of ovalbumin-induced allergic inflammation of the airways, eosinophil recruitment to the lungs was significantly reduced in iNOS −/− mice, possibly via enhanced expression of interferon-γ in the absence of iNOS [83] . However, the multifaceted functions of iNOS-derived NO are perhaps best illustrated by two studies of complex inflammatory models, involving distinct immunological mechanisms. MRL\fas lpr mice, which are affected by systemic autoimmune disease and vasculitis, express iNOS at high levels. In these animals deletion of iNOS results in decreased renal vasculitis, indicating a pro-inflammatory effect of iNOSderived NO [84] . However, in the same iNOS −/− animals, the inflammatory response in the synovium and renal glomeruli is unaltered. This illustrates that, even under the influence of the same systemic immune\ inflammatory stimulus, the role of iNOS can vary between tissues in the same animal. Similarly disparate observations were made in a study of cardiac transplant arteriosclerosis in which both wild-type and iNOS −/− mice were used as graft recipients [85] . Early in the allograft rejection, when iNOS expression was predominantly localized to infiltrating leucocytes, iNOS −/− grafts displayed reduced leucocyte infiltration. In contrast, when the allograft was allowed to progress to chronic rejection using immunosuppressive agents, iNOS was expressed predominantly in parenchymal cells, and graft infiltration was enhanced in the absence of iNOS.
Taken together, these findings suggest that, even in the one model of inflammation, the role of iNOS can vary according to its cellular location and temporal expression [85] . NO can potentially influence the functions of numerous cell types involved in the immune response, including endothelial cells, neutrophils, monocyte\mac-rophages, T cells, mast cells and platelets. Clearly, in more complex inflammatory responses, NO can impact upon the function of a greater number of these cell types,
Figure 3 Potential mechanisms whereby iNOS-derived NO may inhibit leucocyte recruitment
Within leucocytes, there is evidence to suggest that NO may modulate cytoskeletal function, and the expression and activity of adhesion molecules. In activated endothelial cells, NO has been shown to inhibit adhesion molecule expression and production of pro-inflammatory cytokines, as well as modulating intracellular oxidant levels.
making the net effect more difficult to discern. Careful examination of individual inflammatory processes is required for complete understanding of this multi-potent mediator.
POTENTIAL MECHANISMS OF THE ANTI-ADHESIVE EFFECT OF iNOS (FIGURE 3) Modulation of endothelial adhesion molecule expression
Critical observations regarding the anti-inflammatory effect of NO have come from in vitro studies examining adhesion molecule expression induced by pro-inflammatory mediators such as LPS and TNF-α. NO, derived from NO donors, has been shown to inhibit LPS-or cytokine-induced expression of the endothelial adhesion molecules ICAM-1, VCAM-1 and E-selectin, and of proinflammatory cytokines such as IL-6 and IL-8 [86, 87] . This effect is due in part to inhibition of activation of the transcription factor nuclear factor-κB (NF-κB). NF-κB is one of the key transcription factors in the inflammatory response, and is involved in promoting the endothelial expression of adhesion molecules and pro-inflammatory cytokines [88] . NO has been shown to inhibit NF-κB activation by inducing the expression and stabilization of IκB-α, a regulatory protein which inhibits translocation of NF-κB to the nucleus [89] .
The possibility that iNOS-derived NO may act via this mechanism in vivo has only recently begun to be investigated. Kawachi et al. [90] examined the expression of VCAM-1 in TNF-α-treated mice. In some tissues, TNF-α-induced VCAM-1 expression was enhanced in iNOS −/− mice, but only when VCAM-1 expression was submaximal. At a higher dose of TNF-α, VCAM-1 expression did not differ between wild-type and iNOS −/− mice. Furthermore, in a SCID (severe combined immunodeficient) mouse model of colitis induced by reconstitution with CD4 + CD45RB high T cells, VCAM-1 expression in the inflamed colon was not altered by continuous iNOS inhibition with L-NIL. These observations suggest that, although under some conditions iNOS may regulate adhesion molecule expression in the inflamed microvasculature, in most instances, and particularly in response to a strong inflammatory stimulus, VCAM-1 expression was not affected by iNOS-derived NO. Further experiments are required to determine whether comparable findings are observed in response to LPS stimulation, and whether other adhesion molecules, such as P-selectin and E-selectin, are differentially affected.
Alterations in leucocyte function
To determine if alterations in leucocyte function were responsible for these observations, we examined inter-actions of leucocytes removed from wild-type and iNOS −/− mice using an in vitro flow chamber assay [77] . At 4 h after LPS administration, wild-type leucocytes underwent minimal interactions with an immobilized adhesion-molecule-coated surface, whereas many more leucocytes from iNOS −/− mice were recruited to this surface. These findings indicated that iNOS-derived NO reduced the ability of leucocytes to interact with an adhesion molecule substrate, providing a plausible explanation for the enhanced leucocyte recruitment observed in vivo in iNOS −/− mice.
Alterations in leucocyte adhesion molecule expression
Given the observation that iNOS-derived NO appears to affect the ability of leucocytes to undergo rolling and adhesive interactions, this raises the question of how the leucocyte adhesive machinery is affected.
Leucocyte rolling
The effect on leucocyte rolling raises the possibility that the leucocyte molecules responsible for rolling are targets of iNOS-derived NO. We examined one candidate molecule, L-selectin, following LPS stimulation in wildtype and iNOS −/− mice and found no difference in Lselectin expression [77] . Similarly, Sato et al. [91] showed that NO had no effect on complement-induced L-selectin shedding by rabbit neutrophils, indicating that it is unlikely that alterations in L-selectin expression are responsible for NO-induced alterations in leucocyte rolling. Another candidate leucocyte receptor is PSGL-1, but at this stage it is not known whether NO plays a role in the regulation of PSGL-1 expression.
Leucocyte adhesion
NO has been shown to inhibit β2-integrin-dependent neutrophil adhesion to a range of substrates, including endothelial cells, as well as inhibiting complementinduced CD18 up-regulation [91, 92] . However, it has been shown that a decrease in endogenous NO production in vivo does not alter expression levels of β2-integrins on neutrophils, as determined using an anti-CD18 antibody [42] . This observation indicated that alterations in β2-integrins are unlikely to be responsible for elevated adhesion when constitutive NO production is inhibited. Clearly, further work is required to determine the role of iNOS-derived NO in the regulation of the leucocyte adhesion molecules.
Modulation of cytoskeletal function
There is evidence that NO modulates cytoskeletal function. The cytoskeleton is integral to the ability of inflammatory leucocytes to undergo various activationrelated processes, including adhesion, shape change, migration, phagocytosis and degranulation [93] . Furthermore, disruption of the leucocyte cytoskeleton has been shown to decrease the number of microvillous projections on the cell surface, and reduce the ability of leucocytes to initiate rolling interactions on P-and Eselectins under flow conditions [94] . Cytoskeletal function is regulated by the ongoing polymerization and depolymerization of actin. Exogenous NO inhibits actin polymerization in human neutrophils, reducing the ability of these cells to adhere to fibronectin [91, 95] . In addition, monocyte spreading and adhesion, which are dependent on an intact cytoskeleton, are inhibited in an autocrine fashion by endothelin-induced NO production [96, 97] . Given these data, it is conceivable that iNOSderived NO could also impact upon leucocyte cytoskeletal function in vivo. However, this intriguing possibility awaits investigation via definitive experiments.
CONCLUSION
iNOS expression is associated with a wide variety of inflammatory responses, leading to the hypothesis that iNOS is a pro-inflammatory molecule. Despite this, the findings of several studies indicate that iNOS-derived NO can inhibit leucocyte adhesion in the microvasculature, suggesting that one of its functions may be to act as an endogenous anti-inflammatory molecule during ongoing inflammation. Nevertheless, in other studies leucocyte recruitment was unaltered or decreased in iNOS −/− mice. One possible explanation for this disparity is the diversity of functions of NO. iNOS-derived NO can impact on a wide variety of cell types and processes that may be active during inflammatory responses, including leucocyte adhesion, apoptosis, microvascular responsiveness, the function of a wide range of enzymes, and gene expression. The net impact of iNOS during inflammatory responses is the sum of all of these effects, and conceivably will vary with the type, location, and perhaps even phase, of the inflammatory response. Prior to iNOS becoming a therapeutic target, arguably inappropriately, much work remains to characterize all of the effects of iNOS over the wide range of inflammatory responses which affect the human microvasculature. 
